(Q38186633)

30 August 2017

title

Modulation of the renin-angiotensin-aldosterone system in heart failure (English)

1 reference

30 August 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24510580%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Chim C. Lang

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24510580%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

J George

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24510580%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

language of work or name

1 reference

1 April 2014

1 reference

Current Atherosclerosis Reports

30 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24510580%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24510580%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24510580%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

403

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24510580%20AND%20SRC:MED&resulttype=core&format=json

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Clinical practice. Systolic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Reverse remodeling in heart failure--mechanisms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

The pathophysiology of aldosterone in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Spironolactone use and renal toxicity: population based longitudinal analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Irbesartan in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Renin, (pro)renin and receptor: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

(Pro)renin receptor triggers distinct angiotensin II-independent extracellular matrix remodeling and deterioration of cardiac function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Clinical pharmacokinetics and pharmacodynamics of aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Renin inhibition in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Influence of candoxatril on plasma brain natriuretic peptide in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Glucocorticoids and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Aldosterone synthase inhibition in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0403-7

How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?

21 January 2018

1 reference

12 December 2020

Phase II PARAMOUNT trial of LCZ696

1 reference

12 December 2020

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

1 reference

12 December 2020

The perindopril in elderly people with chronic heart failure (PEP-CHF) study

1 reference

12 December 2020

Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure

1 reference

12 December 2020

Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension

1 reference

12 December 2020

Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])

1 reference

12 December 2020

Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials

1 reference

12 December 2020

The effect of digoxin on mortality and morbidity in patients with heart failure

1 reference

12 December 2020

Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure

1 reference

12 December 2020